A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Trial Profile

A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Binimetinib (Primary) ; Sotrastaurin (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jul 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2014 Planned number of patients changed from 125 to 157 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top